Navigation Links
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Date:9/12/2008

mitted to provide minimum levels of physician details and promotional spending for Ranexa for a specified period of time.

In addition to upfront and milestone payments and potential development expense reimbursement, CV Therapeutics is entitled to receive royalties on sales of Ranexa in the territories covered by the agreement. Under the terms of the agreement, Menarini is expected to launch Ranexa in Germany and the UK in the first quarter of 2009 with commercial launch in the other licensed territories expected following formal pricing and reimbursement authorizations in those countries.

"Menarini is a successful and growing organization which leads the European pharmaceutical industry in physician detailing and cardiovascular experience. Their proven ability to launch and promote cardiovascular products suggests they are exceptionally well positioned to launch Ranexa to both specialists and primary care physicians," said Louis G. Lange, chairman and chief executive officer of CV Therapeutics.

In the past decade, Menarini has expanded its presence in the European Union and the other licensed territories, growing revenues more than 150 percent to euro 2.5 billion in 2007.

Global pharmaceutical companies such as AstraZeneca, Bristol Meyers Squibb, Daiichi Sankyo, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, and Pfizer have selected Menarini to sell some of their most important brands in Europe, including atorvastatin (Lipitor(R)), sitagliptin (Januvia(R)), esomeprazole (Nexium(R)), fluticasone/salmeterol (Advair(R)), nebivolol (Nebilet(R)) and olmesartan (Benicar(R)).

"Ranexa represents an important first in class product which we believe will help meet the substantial unmet needs of patients across Europe, Central America and South America," said Alberto Aleotti, chairman and chief executive officer of Menarini.

Ranexa(R) (ranolazine prolonged release tablets) is approved for use in Europe as add-on the
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics to Host Investor Day in Milan, Italy on Friday, October 3, 2008
2. Halozyme Therapeutics to Present at Upcoming Investor Conferences
3. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
11. Cell Therapeutics, Inc. Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... May 5 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), ... the early,detection of diseases and personalized health management, ... to its Board of,Directors, Mr. Harry A. Glorikian ... Mr. James Howard-Tripp, Mr. Garth MacRae, Dr. Heiner ...
... EDT -, VALENCIA, Calif., May 5 MannKind ... the first quarter ended,March 31, 2008., For the ... compared to $77.3 million for the first quarter of ... to $58.4 million,for the first quarter of 2008 compared ...
... $14.8 Million ... ... MINNEAPOLIS, May 5 ATS Medical, Inc. (Nasdaq:,ATSI), manufacturer and marketer ... the first,quarter ended March 29, 2008. Revenue for the quarter was ...
Cached Biology Technology:Genenews adds two members to its Board of Directors 2MannKind Corporation Reports First Quarter Financial Results 2MannKind Corporation Reports First Quarter Financial Results 3MannKind Corporation Reports First Quarter Financial Results 4ATS Medical Announces Record Quarterly Revenue and Gross Profit 2ATS Medical Announces Record Quarterly Revenue and Gross Profit 3ATS Medical Announces Record Quarterly Revenue and Gross Profit 4ATS Medical Announces Record Quarterly Revenue and Gross Profit 5ATS Medical Announces Record Quarterly Revenue and Gross Profit 6ATS Medical Announces Record Quarterly Revenue and Gross Profit 7ATS Medical Announces Record Quarterly Revenue and Gross Profit 8ATS Medical Announces Record Quarterly Revenue and Gross Profit 9
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... and other environmental factors led to the historically high number of ... study released today. A team of biologists from several Gulf ... published their findings in the journal PLoS ONE ... to figure out why there were a high number of dolphin ...
... new study answers a question that has baffled researchers for more ... insect that thrives on corn but dies on soybeans persist ... say, has to do with enzyme production in the rootworm gut. ... and Evolution . Crop rotation declined in the middle of ...
... "ready-made" genes from their hosts that in turn help ... by University of British Columbia and University of Ottawa ... called microsporidia, Encephalitozoon hellem and Encephalitozoon ... found in the intestines of vertebrates. In humans, they ...
Cached Biology News:Study points to causes of high dolphin deaths in Gulf of Mexico 2Team discovers how western corn rootworm resists crop rotation 2Team discovers how western corn rootworm resists crop rotation 3
Request Info...
...
... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
Request Info...
Biology Products: